Effect of Evolocumab on Blood Lipid Levels,Platelet Function and Limb Function in Patients with Progressive Stroke
Objective:To investigate the effect of Evolocumab on blood lipid levels,platelet function and limb function in patients with progressive stroke.Method:A total of 90 patients with progressive stroke admitted to Quanzhou First Hospital Affiliated to Fujian Medical University from April 2022 to April 2023 were selected as the study objects,and were divided into control group(45 cases,treated according to conventional treatment)and observation group(45 cases,treated with conventional treatment + Evolocumab)according to random number table method.Blood lipid levels,platelet function,limb function before and after treatment and adverse reactions were compared between the two groups.Result:Before treatment,there were no significant differences in blood lipid levels between the two groups(P>0.05);after treatment,triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and total cholesterol(TC)in two groups were lower than those before treatment,and the observation group were lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the platelet adhesion rate and platelet agglutination rate between the two groups(P>0.05);after treatment,the platelet adhesion rate and platelet agglutination rate of the two groups were lower than those before treatment,and the observation group were lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Before treatment,there were no significant differences in Fugl-Meyer motor function rating scale(FMA)score and modified Barthel index between the two groups(P>0.05);after treatment,the FMA score and modified Barthel index of the two groups were higher than those before treatment,and the observation group were higher than the control group,the differences were statistically significant(P<0.05).Conclusion:In the treatment of patients with progressive stroke,choosing Evolocumab on the basis of conventional treatment can more effectively improve their blood lipid levels,enhance platelet function,and promote the recovery of limb function.
万方数据
维普
